Transcriptional profiling of experimental CD8+ lymphocyte depletion in rhesus macaques infected with simian immunodeficiency virus SIVmac239

Journal of Virology

Volumn 87, Issue 1, 2013, Pages 433-443

  Bosinger, Steven E ^a   Jochems, Simon P ^a,b,d   Folkner, Kathryn A ^a   Hayes, Timothy L ^a   Klatt, Nichole R ^c,e   Silvestri, Guido ^a  

^a EMORY UNIVERSITY   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d INSTITUT PASTEUR   (France)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; CHEMOKINE RECEPTOR CCR5; KI 67 ANTIGEN; RANTES; TRIPARTITE MOTIF PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IN VIVO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VALIDATION PROCESS; VIRUS REPLICATION;

ANIMALS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION PROFILING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALIA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84871947287     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01746-12     Document Type: Article

References (65)

1. Global HIV/AIDS Vaccine Enterprise. 2005. The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med. 2:e25. doi:10.1371/journal.pmed.0020025.
2. Garber DA, Silvestri G, Feinberg MB. 2004. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect. Dis. 4:397-413.
3. Walker BD, Burton DR. 2008. Toward an AIDS vaccine. Science 320: 760-764.
4. Hu SL, Stamatatos L. 2007. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 5:507-513.
5. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. 2008. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6:143-155.
6. Pantophlet R, Burton DR. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24:739-769.
7. Letvin NL. 2007. Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity 27:366-369.
8. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, Pantaleo G. 2006. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211:236-254.
9. Miller JD, Masopust D, Wherry EJ, Kaech S, Silvestri G, Ahmed R. 2005. Differentiation of CD8 T cells in response to acute and chronic viral infections: implications for HIV vaccine development. Curr. Drug Targets Infect. Disord. 5:121-129.
10. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ. 1988. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 336:484-487.
11. Walker BD, Flexner C, Paradis TJ, Fuller TC, Hirsch MS, Schooley RT, Moss B. 1988. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 240:64-66.
12. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
13. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
14. Goulder PJ, Watkins DI. 2004. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 4:630-640.
15. Carrington M, O'Brien SJ. 2003. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54:535-551.
16. Goulder PJ, Watkins DI. 2008. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8:619-630.
17. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-4789.
18. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, Kostrikis LG, Zhang L, Perelson AS, Ho DD. 1999. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991-998.
19. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. 1998. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72:164-169.
20. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+lymphocytes. Science 283:857-860.
21. Metzner KJ, Jin X, Lee FV, Gettie A, Bauer DE, Di Mascio M, Perelson AS, Marx PA, Ho DD, Kostrikis LG, Connor RI. 2000. Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Exp. Med. 191:1921-1931.
22. Lifson JD, Rossio JL, Piatak M, Jr, Parks T, Li L, Kiser R, Coalter V, Fisher B, Flynn BM, Czajak S, Hirsch VM, Reimann KA, Schmitz JE, Ghrayeb J, Bischofberger N, Nowak MA, Desrosiers RC, Wodarz D. 2001. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J. Virol. 75:10187-10199.
23. Schmitz JE, Johnson RP, McClure HM, Manson KH, Wyand MS, Kuroda MJ, Lifton MA, Khunkhun RS, McEvers KJ, Gillis J, Piatak M, Lifson JD, Grosschupff G, Racz P, Tenner-Racz K, Rieber EP, Kuus-Reichel K, Gelman RS, Letvin NL, Montefiori DC, Ruprecht RM, Desrosiers RC, Reimann KA. 2005. Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J. Virol. 79:8131-8141.
24. Veazey RS, Acierno PM, McEvers KJ, Baumeister SH, Foster GJ, Rett MD, Newberg MH, Kuroda MJ, Williams K, Kim EY, Wolinsky SM, Rieber EP, Piatak M, Jr, Lifson JD, Montefiori DC, Brown CR, Hirsch VM, Schmitz JE. 2008. Increased loss of CCR5+ CD45RA-CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys. J. Virol. 82:5618-5630.
25. Elemans M, Seich Al Basatena NK, Klatt NR, Gkekas C, Silvestri G, Asquith B. 2011. Why don't CD8+ T cells reduce the lifespan of SIVinfected cells in vivo? PLoS Comput. Biol. 7:e1002200. doi:10.1371/journal.pcbi.1002200.
26. Klatt NR, Shudo E, Ortiz AM, Engram JC, Paiardini M, Lawson B, Miller MD, Else J, Pandrea I, Estes JD, Apetrei C, Schmitz JE, Ribeiro RM, Perelson AS, Silvestri G. 2010. CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog. 6:e1000747. doi: 10.1371/journal.ppat.1000747.
27. Wong JK, Strain MC, Porrata R, Reay E, Sankaran-Walters S, Ignacio CC, Russell T, Pillai SK, Looney DJ, Dandekar S. 2010. In vivo CD8+ T-cell suppression of SIV viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog. 6:e1000748. doi:10.1371/journal.ppat.1000748.
28. Balamurali M, Petravic J, Loh L, Alcantara S, Kent SJ, Davenport MP. 2010. Does cytolysis by CD8+ T cells drive immune escape in HIV infection? J. Immunol. 185:5093-5101.
29. Mackewicz CE, Blackbourn DJ, Levy JA. 1995. CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc. Natl. Acad. Sci. U. S. A. 92:2308-2312.
30. Walker CM, Moody DJ, Stites DP, Levy JA. 1986. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563-1566.
31. Baier M, Werner A, Bannert N, Metzner K, Kurth R. 1995. HIV suppression by interleukin-16. Nature 378:563.
32. Mackewicz CE, Wang B, Metkar S, Richey M, Froelich CJ, Levy JA. 2003. Lack of the CD8+cell anti-HIV factor in CD8+cell granules. Blood 102:180-183.
33. Mackewicz CE, Yuan J, Tran P, Diaz L, Mack E, Selsted ME, Levy JA. 2003. Alpha-defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 17:F23-F32.
34. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 1811-1815.
35. Moore JP, Trkola A, Dragic T. 1997. Co-receptors for HIV-1 entry. Curr. Opin. Immunol. 9:551-562.
36. Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, Francella N, Sidahmed A, Smith AJ, Cramer EM, Zeng M, Masopust D, Carlis JV, Ran L, Vanderford TH, Paiardini M, Isett RB, Baldwin DA, Else JG, Staprans SI, Silvestri G, Haase AT, Kelvin DJ. 2009. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J. Clin. Invest. 119:3556-3572.
37. Bosinger SE, Hosiawa KA, Cameron MJ, Persad D, Ran L, Xu L, Boulassel MR, Parenteau M, Fournier J, Rud EW, Kelvin DJ. 2004. Gene expression profiling of host response in models of acute HIV infection. J. Immunol. 173:6858-6863.
38. Abel K, Alegria-Hartman MJ, Rothaeusler K, Marthas M, Miller CJ. 2002. The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection. J. Virol. 76:8433-8445.
39. Carthagena L, Bergamaschi A, Luna JM, David A, Uchil PD, Margottin-Goguet F, Mothes W, Hazan U, Transy C, Pancino G, Nisole S. 2009. Human TRIM gene expression in response to interferons. PLoS One 4:e4894. doi:10.1371/journal.pone.0004894.
40. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430.
41. Conlon K, Lloyd A, Chattopadhyay U, Lukacs N, Kunkel S, Schall T, Taub D, Morimoto C, Osborne J, Oppenheim J, Young H, Kelvin D, Ortaldo J. 1995. CD8+and CD45RA+human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1 alpha, interleukin-8 and RANTES. Eur. J. Immunol. 25:751-756.
42. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM. 1988. A human T cell-specific molecule is a member of a new gene family. J. Immunol. 141:1018-1025.
43. Chang TL, Francois F, Mosoian A, Klotman ME. 2003. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. J. Virol. 77:6777-6784.
44. Zaharatos GJ, He T, Lopez P, Yu W, Yu J, Zhang L. 2004. Alphadefensins released into stimulated CD8+ T-cell supernatants are likely derived from residual granulocytes within the irradiated allogeneic peripheral blood mononuclear cells used as feeders. J. Acquir. Immune Defic. Syndr. 36:993-1005.
45. Zhang L, Lopez P, He T, Yu W, Ho DD. 2004. Retraction of an interpretation. Science 303:467.
46. Rehaume LM, Hancock RE. 2008. Neutrophil-derived defensins as modulators of innate immune function. Crit. Rev. Immunol. 28:185-200.
47. Zhang L, Yu W, He T, Yu J, Caffrey RE, Dalmasso EA, Fu S, Pham T, Mei J, Ho JJ, Zhang W, Lopez P, Ho DD. 2002. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298:995-1000.
48. Lusso P. 2006. HIV and the chemokine system: 10 years later. EMBO J. 25:447-456.
49. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E. 2005. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11:1170-1172.
50. Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M, Jr, Kunstman K, Kuhmann SE, Marx PA, Lifson JD, Dufour J, Mefford M, Pandrea I, Wolinsky SM, Doms RW, DeMartino JA, Siciliano SJ, Lyons K, Springer MS, Moore JP. 2003. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J. Exp. Med. 198:1551-1562.
51. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A, De Luca A, Easterbrook P, Gunthard HF, Mallal S, Mussini C, Dalmau J, Martinez-Picado J, Miro JM, Obel N, Wolinsky SM, Martinson JJ, Detels R, Margolick JB, Jacobson LP, Descombes P, Antonarakis SE, Beckmann JS, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Feng S, Telenti A, Goldstein DB. 2009. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 5:e1000791. doi:10.1371/journal.pgen.1000791.
52. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. 2008. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog. 4:e16. doi:10.1371/journal.ppat.0040016.
53. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, Jung JU. 2007. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446:916-920.
54. Tsuchida T, Zou J, Saitoh T, Kumar H, Abe T, Matsuura Y, Kawai T, Akira S. 2010. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity 33:765-776.
55. Nguyen TX, Cole AM, Lehrer RI. 2003. Evolution of primate thetadefensins: a serpentine path to a sweet tooth. Peptides 24:1647-1654.
56. Venkataraman N, Cole AL, Ruchala P, Waring AJ, Lehrer RI, Stuchlik O, Pohl J, Cole AM. 2009. Reawakening retrocyclins: ancestral human defensins active against HIV-1. PLoS Biol. 7:e95. doi:10.1371/journal.pbio.1000095.
57. Ding J, Chou YY, Chang TL. 2009. Defensins in viral infections. J. Innate Immun. 1:413-420.
58. Klotman ME, Chang TL. 2006. Defensins in innate antiviral immunity. Nat. Rev. Immunol. 6:447-456.
59. Zaragoza MM, Sankaran-Walters S, Canfield DR, Hung JK, Martinez E, Ouellette AJ, Dandekar S. 2011. Persistence of gut mucosal innate immune defenses by enteric alpha-defensin expression in the simian immunodeficiency virus model of AIDS. J. Immunol. 186:1589-1597.
60. Agrati C, Cimini E, Sacchi A, Bordoni V, Gioia C, Casetti R, Turchi F, Tripodi M, Martini F. 2009. Activated V gamma 9V delta 2 T cells trigger granulocyte functions via MCP-2 release. J. Immunol. 182:522-529.
61. Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G, Sireci G, Fournie JJ, Dieli F. 2011. Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells. Blood 118:129-138.
62. Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jornvall H, Wigzell H, Gudmundsson GH. 2000. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96:3086-3093.
63. Chalifour A, Jeannin P, Gauchat JF, Blaecke A, Malissard M, N'Guyen T, Thieblemont N, Delneste Y. 2004. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 104:1778-1783.
64. Obata-Onai A, Hashimoto S, Onai N, Kurachi M, Nagai S, Shizuno K, Nagahata T, Matsushima K. 2002. Comprehensive gene expression analysis of human NK cells and CD8(+) T lymphocytes. Int. Immunol. 14: 1085-1098.
65. Freel SA, Saunders KO, Tomaras GD. 2011. CD8(+)T-cell-mediated control of HIV-1 and SIV infection. Immunol. Res. 49:135-146.